Bank of New York Mellon’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-16,454
| Closed | -$255K | – | 4211 |
|
|
2024
Q1 | $255K | Sell |
16,454
-762
| -4% | -$16.4K | ﹤0.01% | 3851 |
|
|
2023
Q4 | $482K | Buy |
17,216
+1,178
| +7% | +$30.9K | ﹤0.01% | 3574 |
|
|
2023
Q3 | $763K | Sell |
16,038
-112
| -0.7% | -$8.55K | ﹤0.01% | 3330 |
|
|
2023
Q2 | $1.55M | Buy |
16,150
+3,627
| +29% | +$395K | ﹤0.01% | 2969 |
|
|
2023
Q1 | $1.42M | Buy |
12,523
+78
| +0.6% | +$8.44K | ﹤0.01% | 2981 |
|
|
2022
Q4 | $1.39M | Buy |
12,445
+105
| +0.9% | +$14.1K | ﹤0.01% | 3036 |
|
|
2022
Q3 | $1.58M | Buy |
12,340
+1,690
| +16% | +$173K | ﹤0.01% | 2976 |
|
|
2022
Q2 | $730K | Sell |
10,650
-626
| -6% | -$53.9K | ﹤0.01% | 3358 |
|
|
2022
Q1 | $1.6M | Buy |
11,276
+245
| +2% | +$37.7K | ﹤0.01% | 3054 |
|
|
2021
Q4 | $1.84M | Sell |
11,031
-2,677
| -20% | -$425K | ﹤0.01% | 3041 |
|
|
2021
Q3 | $1.91M | Buy |
13,708
+679
| +5% | +$133K | ﹤0.01% | 3001 |
|
|
2021
Q2 | $6.21M | Buy |
13,029
+2,657
| +26% | +$1.12M | ﹤0.01% | 2386 |
|
|
2021
Q1 | $4.27M | Sell |
10,372
-544
| -5% | -$250K | ﹤0.01% | 2509 |
|
|
2020
Q4 | $5.35M | Buy |
10,916
+1,517
| +16% | +$888K | ﹤0.01% | 2325 |
|
|
2020
Q3 | $5.32M | Buy |
9,399
+2,758
| +42% | +$917K | ﹤0.01% | 2181 |
|
|
2020
Q2 | $632K | Buy |
6,641
+910
| +16% | +$79.8K | ﹤0.01% | 3358 |
|
|
2020
Q1 | $409K | Buy |
5,731
+119
| +2% | +$7.98K | ﹤0.01% | 3470 |
|
|
2019
Q4 | $387K | Buy |
5,612
+1,058
| +23% | +$78.5K | ﹤0.01% | 3706 |
|
|
2019
Q3 | $365K | Buy |
4,554
+1,356
| +42% | +$89.6K | ﹤0.01% | 3704 |
|
|
2019
Q2 | $205K | Sell |
3,198
-1,244
| -28% | -$118K | ﹤0.01% | 3920 |
|
|
2019
Q1 | $611K | Buy |
4,442
+174
| +4% | +$21.2K | ﹤0.01% | 3453 |
|
|
2018
Q4 | $386K | Buy |
4,268
+301
| +8% | +$42.1K | ﹤0.01% | 3611 |
|
|
2018
Q3 | $602K | Hold |
3,967
| – | – | ﹤0.01% | 3547 |
|
|
2018
Q2 | $683K | Sell |
3,967
-683
| -15% | -$112K | ﹤0.01% | 3462 |
|
|
2018
Q1 | $682K | Buy |
4,650
+495
| +12% | +$94.9K | ﹤0.01% | 3425 |
|
|
2017
Q4 | $842K | Sell |
4,155
-70
| -2% | -$14.4K | ﹤0.01% | 3345 |
|
|
2017
Q3 | $1.35M | Buy |
4,225
+198
| +5% | +$54.1K | ﹤0.01% | 3050 |
|
|
2017
Q2 | $910K | Sell |
4,027
-66
| -2% | -$13.6K | ﹤0.01% | 3300 |
|
|
2017
Q1 | $923K | Sell |
4,093
-3
| -0.1% | -$609 | ﹤0.01% | 3289 |
|
|
2016
Q4 | $811K | Buy |
4,096
+723
| +21% | +$158K | ﹤0.01% | 3370 |
|
|
2016
Q3 | $829K | Buy |
3,373
+509
| +18% | +$179K | ﹤0.01% | 3270 |
|
|
2016
Q2 | $1.66M | Buy |
2,864
+899
| +46% | +$527K | ﹤0.01% | 2828 |
|
|
2016
Q1 | $1.04M | Buy |
1,965
+209
| +12% | +$109K | ﹤0.01% | 3034 |
|
|
2015
Q4 | $1.23M | Buy |
1,756
+750
| +75% | +$493K | ﹤0.01% | 3034 |
|
|
2015
Q3 | $597K | Buy |
+1,006
| New | +$821K | ﹤0.01% | 3500 |
|
Other funds holding MCRB
FP
TCM
Bank of New York Mellon's MCRB Position: Q2 2024 in Review
Bank of New York Mellon sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 16,454 shares — an estimated $255K sold.
Bank of New York Mellon first reported a position in MCRB in Q3 2015 and held it in 35 quarters. The position peaked at $6.21M in Q2 2021. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.
- Bank of New York Mellon reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
- Bank of New York Mellon sold 16,454 Seres Therapeutics shares in Q2 2024, an estimated $255K.
- Bank of New York Mellon first reported a position in Seres Therapeutics in Q3 2015 and held it in 35 quarters.
- Bank of New York Mellon's Seres Therapeutics position peaked at $6.21M in Q2 2021.
- 93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.
Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.